Intellia Therapeutics 2024年第四季度GAAP每股亏损$1.27,优于预期的$1.36,销售额为1287万美元,优于预期的853万美元

财报速递02-27
Intellia Therapeutics(NASDAQ:NTLA)报告季度每股亏损1.27美元,优于分析师预期的亏损1.36美元,增幅为6.62%。这相比去年同期每股亏损1.46美元,增加了13.01%。该公司报告季度销售额为1287万美元,优于分析师预期的853万美元,增幅达50.89%。这相比去年同期的负192万美元,增加了771.57%。

以上内容来自Benzinga Earnings专栏,原文如下:

Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.36) by 6.62 percent. This is a 13.01 percent increase over losses of $(1.46) per share from the same period last year. The company reported quarterly sales of $12.87 million which beat the analyst consensus estimate of $8.53 million by 50.89 percent. This is a 771.57 percent increase over sales of $(1.92 million) the same period last year.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法